BM5131 Coagulation factor VIII (F8) antibody

See related secondary antibodies

Search for all "Coagulation factor VIII (F8)"

0.5 mg / €390.00
Please visit the country specific website of OriGene Technologies or contact your local Distributor to buy this product.

Quick Overview

Mouse anti Human Coagulation factor VIII (F8) MH104

BM5131

Product Description for Coagulation factor VIII (F8)

Mouse anti Human Coagulation factor VIII (F8) MH104.
Presentation: Purified
Product is tested for Frozen Sections, Enzyme Immunoassay, Western blot / Immunoblot.

Properties for Coagulation factor VIII (F8)

Product Category Primary Antibodies
Quantity 0.5 mg
Synonyms AHF, Antihemophilic factor, F8C, Procoagulant component
Presentation Purified
Reactivity Hu
Applications C, E, WB
Clonality Monoclonal
Clone MH104
Host Mouse
Isotype IgG2a
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer OriGene Technologies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

Immunogen
Swiss Prot Num:
P00451
Immunogen:
Human factor VIII antigen
GeneID:
2157
Isotype control AM03096PU-N
Application ELISA: 1:5,000; detection and quantitation of human factor VIII.
Immunoblotting.
Immunohistochemistry on frozen sections.
Background Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.
General Readings
  1. Stel HV, van der Kwast TH, Veerman EC: Detection of factor VIII / coagulant antigen in human liver tissue. Nature 303, 530-532 (1983)
Storage Prior to reconstitution store at 2-8°C.
Following reconstitution store the antibody at -20°C.
Avoid repeated freezing and thawing.
Shelf life: one year from despatch.
Format
Purification:
Protein A affinity chromatography
Buffer System:
PBS, pH 7.4 containing 0.09 % NaN3, 0.5% BSA
State:
Lyophilized purified IgG
Purified
Reconstitution:
Restore in 1 ml dist. water
Specificity
Specificity:
MH104 is specific for human factor VIIIc, a 300 kD protein present in plasma in a complex with von Willebrandt factor. Involved in the clotting cascade (activated by thrombin) by forming a complex with factor IXa, calcium, and phospholipids.
Elevated levels of factor VIII have been associated with acute and chronic liver diseases, vascular disorders, diabetes and with acutephase reactions.
Species:
Human.
Gene ID 2157

Accessory Products

Proteins and/or Positive Controls

Proteins for Coagulation factor VIII (F8) (17 products)

Catalog No. Species Pres. Purity   Source  

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 97.0% as determined by SDS-PAGE. CHO cells
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 97.0% as determined by SDS-PAGE. CHO cells
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 97.0% as determined by SDS-PAGE. CHO cells
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 98 % purified by proprietary chromatographic techniques, purity is greater than 98.0 % as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Plasma
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 98 % purified by proprietary chromatographic techniques, purity is greater than 98.0 % as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Plasma
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 98 % purified by proprietary chromatographic techniques, purity is greater than 98.0 % as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Plasma
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 98 % Purified by proprietary chromatographic techniques, purity is reater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
CHO cells
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 98 % Purified by proprietary chromatographic techniques, purity is reater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
CHO cells
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified > 98 % Purified by proprietary chromatographic techniques, purity is reater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
CHO cells
  OriGene Technologies GmbH

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human
  Abnova Taiwan Corp.

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified
  Abnova Taiwan Corp.

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human Purified
  Abnova Taiwan Corp.

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human 12.5% SDS-PAGE Stained with Coomassie Blue. in vitro transl.
  Abnova Taiwan Corp.

Coagulation factor VIII (F8)

Coagulation factor VIII (F8) Human 12.5% SDS-PAGE Stained with Coomassie Blue. in vitro transl.
  Abnova Taiwan Corp.

Positive controls for Coagulation factor VIII (F8) (3 products)

Catalog No. Species Pres. Purity   Source  

F8 293T Cell Transient Overexpression Lysate(Denatured)

F8 293T Cell Transient Overexpression Lysate(Denatured)
  Abnova Taiwan Corp.

F8 overexpression lysate

F8 overexpression lysate
  OriGene Technologies, Inc.

Factor VIII Lysate

Western Blot: Factor VIII Lysate [NBL1-10413] - Western Blot experiments. 
Left-Control; Right -Over-expression Lysate for F8
  Novus Biologicals Inc.
  • LinkedIn